Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 24, 2026Science Translational Medicine

Premature senescence impairs hematopoietic stem cell function during sickle cell disease in mice and humans

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAditya BarvePDPreeti DabasACAdam Cornwell

Discussion

Loading...

Member takes

Overview

Randomized trial investigates HSC dysfunction in sickle cell disease, suggesting therapies may improve outcomes.

Key Points

  • The study aims to explore how premature senescence affects hematopoietic stem cell function in sickle cell disease.
  • Analyzed bone marrow HSPCs from mice and individuals with SCD for molecular stress signatures.
  • Conducted flow cytometry and transplantation studies to assess HSPC function.
  • Applied senescence-targeting therapies ABT-263 and dasatinib combined with quercetin.
  • SCD HSPCs showed marked transcriptomic dysregulation and impaired mitogen responses.
  • SCD mice exhibited a 50% reduction in functional bone marrow HSPCs and poor colony-forming ability in humans.
  • Senescence-targeting therapy improved HSPC function in both mice (p<0.01) and human-derived cells.

Cite This Study

Barve et al. (2026) studied this question.

synapsesocial.com/papers/6a630179395161722cd16192https://doi.org/10.1126/scitranslmed.adv0628
View Full Paper
Ask AI
Bookmark
Share